The correlation between ACOT2 expression levels and clinical characteristics, including age, gender, patients' race, WBC counts, BM blasts, PB blasts, cytogenetic risks, and FAB classification were analyzed, and the results suggested that ACOT2 did not differ significantly with most of these clinical characteristics in AML except for FAB classification and cytogenetics (Table 1). This evidence concerns the gene ACOT2 and acute myeloid leukemia.